Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX Vaccine Boosting in Pancreatic Cancer
NCT00389610Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2006
- Primary completion
- Oct 2021
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GVAX pancreatic cancer vaccine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of Patients Experiencing a Grade 3 or Above Treatment-Related Toxicity at 14 years. Started Sep 2006; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00389610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389610.